Management of IDH-Mutant Glioma in Adults
For adult patients with IDH-mutant glioma, management begins with maximal safe surgical resection, followed by a grade-specific and risk-stratified approach: Grade 2 tumors may be observed post-resection or treated with vorasidenib if residual disease exists, while Grade 3 tumors require radiotherapy followed by adjuvant chemotherapy (temozolomide for astrocytomas, PCV for oligodendrogliomas). 1, 2
Initial Management: Surgery First
Maximal safe surgical resection is the cornerstone of treatment for all IDH-mutant gliomas, regardless of grade. The extent of resection directly impacts progression-free survival, seizure control, and timing of subsequent interventions. 2
Grade 2 IDH-Mutant Gliomas: Risk-Stratified Approach
Low-Risk Patients (Observation Appropriate)
Observation alone is appropriate after gross-total or near-total resection in:
- Younger patients (approximately <40-45 years)
- Asymptomatic or seizure-only presentation
- Minimal to no residual disease on post-operative MRI
- Stable serial imaging 2
High-Risk Patients Requiring Treatment
For patients requiring post-surgical treatment (age ≥40 years, subtotal resection, or significant residual disease):
First-line option: Radiotherapy (50-54 Gy in 1.8-2 Gy fractions) followed by PCV chemotherapy (procarbazine, lomustine, vincristine) - this is the established standard based on RTOG 9802, which demonstrated OS prolongation from 7.8 to 13.3 years. 2
Alternative first-line option (FDA-approved 2024): Vorasidenib for patients with measurable residual or recurrent non-enhancing Grade 2 IDH-mutant glioma (astrocytoma or oligodendroglioma) with susceptible IDH1 or IDH2 mutations. The INDIGO trial showed vorasidenib significantly improved progression-free survival (HR 0.39) and delayed time to next intervention (HR 0.26) compared to placebo. 1
When to Choose Vorasidenib Over Radiochemotherapy
Vorasidenib is preferred when:
- Measurable, non-enhancing, clinically stable residual disease exists
- Patient prioritizes preservation of cognition, work capacity, or fertility
- Radiotherapy and chemotherapy can reasonably be deferred
- No rapid growth, symptomatic mass effect, or enhancement present 1, 3
Radiotherapy + PCV remains preferred for:
- Rapid tumor growth on serial imaging
- Symptomatic mass effect or neurological decline
- New or nodular enhancement suggesting transformation
- Uncontrolled seizures despite medical management
- High-risk molecular features (e.g., CDKN2A/B homozygous deletion)
- Suspected grade transformation 3, 4
Critical caveat: Vorasidenib should not be viewed as a universal substitute for definitive radiochemotherapy—it is an active-delay strategy that postpones but does not replace the need for cytoreductive therapy in most patients. 3
Grade 3 IDH-Mutant Gliomas: Definitive Treatment Required
IDH-Mutant Astrocytoma, Grade 3
Standard treatment: Radiotherapy (54-60 Gy in 1.8-2 Gy fractions) followed by adjuvant temozolomide chemotherapy, based on the CATNON trial. 2
IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma, Grade 3
Standard treatment: Radiotherapy (54-60 Gy in 1.8-2 Gy fractions) followed by PCV chemotherapy, based on EORTC 26951 and RTOG 9402 trials. 2
Grade 4 IDH-Mutant Astrocytoma
Standard treatment: Temozolomide-based chemoradiotherapy (54-60 Gy in 1.8-2 Gy fractions), potentially without concomitant temozolomide during radiation. This is extrapolated from both IDH-mutant anaplastic astrocytoma data and glioblastoma protocols. 2
Treatment at Progression
For Grade 2-3 tumors progressing after initial surgery and radiotherapy:
- Temozolomide is the standard chemotherapy option 2
- Consider repeat surgery if gross-total resection is achievable 2
- Nitrosoureas are alternative chemotherapy options
- Bevacizumab may be used for symptom control, though antitumor efficacy is uncertain 2
Surveillance Strategy
Follow-up intervals: Every 3-6 months with neurological examination and MRI 2
Indicators of treatment failure requiring intervention:
- Sustained T2/FLAIR volumetric growth over serial scans
- New or progressive enhancement
- Worsening seizure control
- Steroid requirement
- Functional or neurological decline
- Clinical need for next intervention 3
Important principle: Judge treatment failure by trajectory across multiple scans, not a single imaging study. 3
Key Clinical Pitfalls to Avoid
Do not defer molecular diagnosis: IDH mutation status and 1p/19q codeletion testing are mandatory for treatment planning—observation without integrated molecular diagnosis should only occur in exceptional circumstances. 4
Do not use temozolomide alone as a universal substitute for radiotherapy: While chemotherapy alone may be considered when radiotherapy is not feasible, the NOA-04 trial showed chemotherapy alone (PCV or temozolomide) is not superior to radiotherapy alone. 2
Do not apply vorasidenib to enhancing or rapidly progressive tumors: This agent is specifically for non-enhancing, stable Grade 2 disease—it is not appropriate for aggressive or transforming tumors. 1, 3
Do not delay radiochemotherapy in high-risk scenarios: While early radiotherapy prolongs PFS, the survival benefit of combined radiochemotherapy in high-risk Grade 2 tumors (RTOG 9802) justifies upfront treatment rather than waiting for progression. 2